2790 Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices 

Æ That using D&B’s product is likely 

to allow a business to have its 

previously unreported commercial 

payment experiences added to its credit 

report; 

Æ That D&B will actively assist a 

business in adding its unreported 

commercial payment experiences to its 

credit report; 

Æ That using D&B’s product is likely 

to help a business build or improve its 

credit report; 

Æ The ease with which information or 

payment experiences can be added to a 

business’s credit report; and 

Æ That D&B’s product is needed when 

it is not, and that a product will enable 

a prospective customer to have a 

‘‘complete’’ file. 

• Part I also features ancillary relief 

relating to the challenged conduct by 

prohibiting misrepresentations relating 

to what payment experiences customers 

can add, as well as to D&B’s renewal 

and charging practices. 

• Part II provides additional specific 

relief relating to D&B’s renewal and 

charging practices for products covered 

under the Proposed Order, to make sure 

that D&B makes clear disclosures about 

renewals both before a customer 

subscribes and during the period of the 

subscription. 

• Parts III and IV require D&B to make 

certain disclosures to potential 

customers of CreditBuilder products, so 

that those potential customers can make 

better informed decisions about whether 

to purchase the products. 

• Part V sets out specific 

requirements for D&B to follow when a 

business disputes information that D&B 

reports about it. The requirements of 

this Part V apply generally and are not 

limited only to D&B customers. 

• Part VI requires D&B to offer 

refunds (or partial refunds) to certain 

customers and former customers of 

CreditBuilder products. Refund or 

partial refund eligibility under the 

Proposed Order will depend on 

customers’ specific circumstances and 

how they used or attempted to use their 

CreditBuilder products. 

• Part VII requires D&B to send 

notices to all current customers of paid 

products covered under the Proposed 

Order that automatically renew. 

Parts VIII through XII are reporting 

and compliance provisions. Part VIII 

mandates that D&B acknowledge receipt 

of the Proposed Order and, for three 

years, distribute the Proposed Order to 

certain employees and agents and 

secure acknowledgments from 

recipients of the Proposed Order. Part IX 

requires D&B to submit compliance 

reports to the FTC one year after the 

order’s issuance and submit additional 

reports when certain events occur. Part 

X requires that, for 10 years, D&B 

creates certain records and retain them 

for at least 5 years. Part XI provides for 

the FTC’s continued compliance 

monitoring of D&B’s activity during the 

Proposed Order’s effective dates. Part 

XII is a provision ‘‘sunsetting’’ the 

Proposed Order after 20 years, with 

certain exceptions. 

The purpose of this analysis is to 

facilitate public comment on the 

Proposed Order. It is not intended to 

constitute an official interpretation of 

the complaint or Proposed Order, or to 

modify in any way the Proposed Order’s 

terms. 

By direction of the Commission. 

April J. Tabor, 

Secretary. 

[FR Doc. 2022–00938 Filed 1–18–22; 8:45 am] 

BILLING CODE 6750–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Patient Safety Organizations: 

Voluntary Relinquishment for the 

Theator, Inc. PSO 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), Department of 

Health and Human Services (HHS). 

ACTION: Notice of delisting. 

SUMMARY: The Patient Safety and 

Quality Improvement Final Rule 

(Patient Safety Rule) authorizes AHRQ, 

on behalf of the Secretary of HHS, to list 

as a patient safety organization (PSO) an 

entity that attests that it meets the 

statutory and regulatory requirements 

for listing. A PSO can be ‘‘delisted’’ by 

the Secretary if it is found to no longer 

meet the requirements of the Patient 

Safety and Quality Improvement Act of 

2005 (Patient Safety Act) and Patient 

Safety Rule, when a PSO chooses to 

voluntarily relinquish its status as a 

PSO for any reason, or when a PSO’s 

listing expires. AHRQ accepted a 

notification of proposed voluntary 

relinquishment from the Theator, Inc. 

PSO, PSO number P0218, of its status as 

a PSO, and has delisted the PSO 

accordingly. 

DATES: The delisting was effective at 

12:00 Midnight ET (2400) on December 

22, 2021. 

ADDRESSES: The directories for both 

listed and delisted PSOs are ongoing 

and reviewed weekly by AHRQ. Both 

directories can be accessed 

electronically at the following HHS 

website: http://www.pso.ahrq.gov/listed. 

FOR FURTHER INFORMATION CONTACT: 

Cathryn Bach, Center for Quality 

Improvement and Patient Safety, AHRQ, 

5600 Fishers Lane, MS 06N100B, 

Rockville, MD 20857; Telephone (toll 

free): (866) 403–3697; Telephone (local): 

(301) 427–1111; TTY (toll free): (866) 

438–7231; TTY (local): (301) 427–1130; 

Email: pso@ahrq.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

Background 

The Patient Safety Act, 42 U.S.C. 

299b–21 to 299b–26, and the related 

Patient Safety Rule, 42 CFR part 3, 

published in the Federal Register on 

November 21, 2008 (73 FR 70732– 

70814), establish a framework by which 

individuals and entities that meet the 

definition of provider in the Patient 

Safety Rule may voluntarily report 

information to PSOs listed by AHRQ, on 

a privileged and confidential basis, for 

the aggregation and analysis of patient 

safety work product. 

The Patient Safety Act authorizes the 

listing of PSOs, which are entities or 

component organizations whose 

mission and primary activity are to 

conduct activities to improve patient 

safety and the quality of health care 

delivery. 

HHS issued the Patient Safety Rule to 

implement the Patient Safety Act. 

AHRQ administers the provisions of the 

Patient Safety Act and Patient Safety 

Rule relating to the listing and operation 

of PSOs. The Patient Safety Rule 

authorizes AHRQ to list as a PSO an 

entity that attests that it meets the 

statutory and regulatory requirements 

for listing. A PSO can be ‘‘delisted’’ if 

it is found to no longer meet the 

requirements of the Patient Safety Act 

and Patient Safety Rule, when a PSO 

chooses to voluntarily relinquish its 

status as a PSO for any reason, or when 

a PSO’s listing expires. Section 3.108(d) 

of the Patient Safety Rule requires 

AHRQ to provide public notice when it 

removes an organization from the list of 

PSOs. 

AHRQ has accepted a notification of 

proposed voluntary relinquishment 

from the Theator, Inc. PSO to 

voluntarily relinquish its status as a 

PSO. Accordingly, the Theator, Inc. 

PSO, P0218, was delisted effective at 

12:00 Midnight ET (2400) on December 

22, 2021. 

More information on PSOs can be 

obtained through AHRQ’s PSO website 

at http://www.pso.ahrq.gov. 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices 2791 

Dated: January 12, 2022. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2022–00906 Filed 1–18–22; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

DP22–001, Real-World Effectiveness of 

Structured Lifestyle Interventions in 

Preventing Type 2 Diabetes. 

Date: March 23, 2022. 

Time: 10:30 a.m.–6:00 p.m., EDT. 

Place: Teleconference. 

Agenda: To review and evaluate grant 

applications. 

FOR FURTHER INFORMATION CONTACT: Jaya 

Raman Ph.D., Scientific Review Officer, 

National Center for Chronic Disease 

Prevention and Health Promotion, CDC, 

4770 Buford Highway, Mailstop S107–8, 

Atlanta, Georgia 30341–3717, 

Telephone: (770) 488–6511; Email: 

JRaman@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–00868 Filed 1–18–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

DP22–002, Epidemiology of Lupus: 

Longitudinal Studies in PopulationBased Cohorts. 

Date: March 17, 2022. 

Time: 11:00 a.m.–6:00 p.m., EDT. 

Place: Teleconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: Jaya 

Raman, Ph.D., Scientific Review Officer, 

National Center for Chronic Disease and 

Health Promotion, CDC, 4770 Buford 

Highway, Mailstop S107–8, Atlanta, 

Georgia 30341–3717, Telephone: (770) 

488–6511, Email: JRaman@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–00867 Filed 1–18–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

[Docket No. CDC–2022–0003] 

Draft Policy Statement for Biosafety 

Level 4 (BSL–4) and Animal BSL–4 

(ABSL–4) Laboratory Verification; 

Notice of Availability 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of availability and 

comment. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC) in the 

Department of Health and Human 

Services (HHS) announces the opening 

of a docket to obtain comment on a draft 

policy statement regarding Biosafety 

Level 4 (BSL–4)/Animal Biosafety Level 

4 (ABSL–4) verification requirements. 

The policy statement, once finalized, 

will assist individuals and entities in 

verifying that the facility design 

parameters and operational procedures, 

including heating, ventilation, and air 

conditioning (HVAC) systems, in BSL– 

4 and/or ABLS–4 laboratories are 

functioning as intended to meet the 

biosafety sufficiency requirement in the 

HHS/CDC select agent regulations. 

DATES: Submit written or electronic 

comments by March 21, 2022. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2022– 

0003, by either of the following 

methods. 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Division of Select Agents and 

Toxins, Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, 

Mailstop H21–7, Atlanta, Georgia 30329. 

Instructions: All submissions received 

must include the Agency name and 

Docket No. CDC–2022–0003. All 

relevant comments received will be 

posted without change to http://

www.regulations.gov, including any 

personal information provided. Do not 

send comments by email. CDC does not 

accept comments by email. 

Docket Access: For access to the 

docket to read background documents 

or comments received, or to download 


jspears on DSK121TN23PROD with NOTICES1